Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 435 of 5804
-
New drug KarXT aims to tame bipolar mania in major trial
Symptom relief Recruiting nowThis is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compar…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Nicotine pouches vs. patches: can they help appalachian smokers quit cigarettes and cut cancer risk?
Disease control Recruiting nowThis clinical trial compares the use of oral nicotine pouches to nicotine replacement therapy, consisting of nicotine patches and lozenges, to reduce cigarette use in smokers living in rural Appalachia. The lung and oral cancers that plague Appalachia are fueled by cigarette smok…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New antibody drug aims to stop lung cancer relapse in its tracks
Disease control Recruiting nowThis is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Heart drug may shield tiny babies from deadly Post-Surgery syndrome
Prevention Recruiting nowThe goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine i…
Phase: PHASE3 • Sponsor: NICHD Neonatal Research Network • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New hope for liver cancer: targeted drug ABSK-011 enters phase 2 trial
Disease control Recruiting nowThis is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. …
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Brain zaps could predict who gets relief from stubborn depression
Symptom relief ENROLLING_BY_INVITATIONThe primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive…
Phase: NA • Sponsor: Semmelweis University • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
New hope for young cancer patients: drug duo targets tough tumors
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come back after a period of improvement (relaps…
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to boost remission in rare blood cancer
Disease control Recruiting nowThis phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two dr…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for tough prostate cancer: Immune-Engaging drug enters human trials
Disease control Recruiting nowThe goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lung cancer screening on wheels: can mobile vans save more lives?
Prevention Recruiting nowLung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current …
Sponsor: Hospices Civils de Lyon • Aim: Prevention
Last updated Jun 26, 2026 15:10 UTC
-
New cream could ease painful skin bumps for HS sufferers
Symptom relief OngoingThe purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Psychedelics take on alcoholism: psilocybin vs ketamine in new trial
Disease control Recruiting nowThis study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will …
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New blood test could speed up stroke diagnosis and save lives
Diagnosis Recruiting nowIntracerebral hemorrhage carries high rates of mortality and disability, imposes a significant societal burden. Based on findings from our previous multicenter randomized controlled clinical trial (INTERACT4), we revealed that initiating intensive blood pressure reduction therapy…
Sponsor: Shanghai East Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail shows promise against tough cancers
Disease control Recruiting nowAn open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Phase: PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Jail-Based hep c cure program shows promise in pilot study
⭐️ CURE ⭐️ Recruiting nowThe goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HC…
Phase: PHASE4 • Sponsor: Lifespan • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
New hope for blood cancer patients: experimental combo enters final testing phase
Disease control Recruiting nowThe goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonr…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for stomach and bowel cancers? experimental drug enters human trials
Disease control Recruiting nowThis study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug could ease painful muscle condition and cut steroid use
Disease control OngoingThe primary objective of the study is to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously every 2 weeks compared with placebo in participants with polymyalgia rheumatica (PMR). The secondary objectives are to evaluate the steroid-sparing effect, inflamm…
Phase: PHASE3 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Brain metastases breakthrough? scientists probe how a powerful drug crosses into the brain
Knowledge-focused Recruiting nowApproximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery/radiotherapy) are associated with significant complications, and systemic treatments have limited efficacy. Although new-generation ADC drugs, such as trastuzumab deruxtecan, ha…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to tackle melanoma that resists treatment
Disease control Recruiting nowThere is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas. The combination of enfortumab/vedotin (EV) and pembrolizumab has shown synergistic e…
Phase: PHASE2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 26, 2026 17:53 UTC